PARP Inhibitors for Cancer Therapy

Ken Yu Lin, W. Lee Kraus

Research output: Contribution to journalShort survey

36 Scopus citations

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

Original languageEnglish (US)
Number of pages1
JournalCell
Volume169
Issue number2
DOIs
StatePublished - Apr 6 2017
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this